oninterventional Study of Safety, Efficacy, Adherence, and Health Related Quality of Life in Patients Receiving a Once Daily Single Tablet Regimen for HIV 1 Infection in GermanySTR-NIS – (STRike)

• Conditions: B24; Unspecified human immunodeficiency virus [HIV] disease

• Registration Number: DRKS00000722
• Lead Sponsor: Gilead Sciences GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-02-25
• Study Completion: 2016-06-24
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 874

Inclusion Criteria

Arm 1 and 2: Adults with HIV-1-infection, who are with their current antiretroviral combination therapy virologically suppressed (HIV-1-RNA < 50 copies/ml) for at least three months.
Arm 3: Antiretroviral naive adults with HIV-1-infection and viral load of <= 100.000 copies HIV-1-RNA/ml
arm 4 - Adults with HIV-1 infection, who are antroretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild

Exclusion Criteria

Patients not fulfilling the inclusion criteria.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral load (HIV RNA) at month 24

Secondary Outcome Measures

Name	Time	Method
SF 36 Quality of life (change from Baseline, each visit)